| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Immunology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Immunology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Cell Therapies | Immunology |
Recent Updates
Recently added Catalysts
MiNK Therapeutics, Inc.$11.97
+0.27 (+2.31%)
F 14Pipeline Score Biotech · Pre-Clinical
Market Cap
59.63 M
EPS
-2.50
P/E Ratio
-
Value Trade
472.40 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
1.20 M
Operating CF
-1.73 M
Total Assets
10.38 M
Total Liabilities
10.38 M
Equity
-12.69 M
10.24 %
Week
9.92 %
1 Month
4.33 %
3 Month
5.93 %
6 Month
-90.97 %
5 Year
-90.97 %
All Time
Cash Data
Cash Position
9.53 M
Monthly Burn
578.00 K
Runway
13.8 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
13.21 K
52 Week Range
8.48 - 18.17
% held by Insiders
61.09 %
% held by Institutions
2.54 %
Enterprise Value
49.19 M
Total Shares
4.98 M
Short %
5.13 %
Float Shares
1.95 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MiNK Therapeutics, Inc.
204Total events
7Upcoming
23Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
TBD
T3Additional Data
Subscribe to view catalyst details
TBD
T3IND Enabling Complete
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutagenT-797Clinical Data
Subscribe to view catalyst details
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F14
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Micro Cap (rank 832 of 923)
Percentile RankMiNK Therapeutics, Inc. has significant pipeline risk (14/100).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| agenT-797 Small molecule | Respiratory Distress Syndrome, Adult | Phase 1 | NCT04582201 | 7% | $557M | - | 20 | - | - | — | - | - |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
agenT-797 | Coccidioides immitis infection | Phase 2 | 2026-05-20 | Suppression of both fungal and bacterial pathogens; Active immune cell recruitment into the lung; Reduced early inflammatory signaling; Activation of tissue repair and immune regulatory pathways Read More | MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications Read More | |
agenT-797 | Coccidioides immitis infection | Phase 2 | 2026-05-20 | Suppression of both fungal and bacterial pathogens; Active immune cell recruitment into the lung; Reduced early inflammatory signaling; Activation of tissue repair and immune regulatory pathways Read More | MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications Read More | |
agenT-797 | Coccidioides immitis infection | Phase 2 | 2026-05-20 | Suppression of both fungal and bacterial pathogens; Active immune cell recruitment into the lung; Reduced early inflammatory signaling; Activation of tissue repair and immune regulatory pathways Read More | MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INKT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INKT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INKT▲ +2.3%today
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
MiNK Therapeutics will report its Q2 2026 financial results on August 13, 2026, and will host a conference call to discuss these results and provide updates on its iNKT cell therapy, agenT-797, for acute lung injury. The call will include new clinical data and information about a named-patient program. MiNK is focused on developing innovative immune therapies.
Read more →INKT▲ +6.7%on this news
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
MiNK Therapeutics has announced its virtual Annual Shareholders Meeting scheduled for June 17, 2026, at 9:30 a.m. ET. Shareholders can register starting at 9:15 a.m. ET, and guests can listen in without a control number. The company is known for its pioneering work in allogeneic iNKT cell therapies aimed at treating immune dysfunction.
Read more →INKT▲ +19.8%on this news
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics has initiated a randomized Phase 2 trial for agenT-797 in patients with acute lung injury and critical illness. The first patient was dosed at a medical facility in Ukraine shortly after receiving approval from the Ministry of Health. This trial aims to evaluate the efficacy of agenT-797 compared to a placebo, focusing on critical ICU outcomes. Preliminary data is expected in the second half of 2026.
Read more →INKTMiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
MiNK Therapeutics announced positive new clinical findings on its allogeneic iNKT cell therapy, agenT-797, presented at ATS 2026 and published in Clinical Immunology Communications. The data indicated significant immune restoration and pathogen suppression in a critically ill patient with multiple severe infections. Following treatment with agenT-797 and the IL-15 superagonist N-803, researchers noted reduced inflammatory signaling and activation of tissue repair pathways. However, the case was complicated by cardiac-related issues leading to the patient's transition to comfort care.
Read more →INKTMiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
MiNK Therapeutics has initiated a randomized Phase 2 trial for its iNKT cell therapy, agenT-797, targeting severe acute lung injury and respiratory distress. The trial aims to evaluate the therapy's efficacy alongside standard care, with preliminary results expected in late 2026. The company also reported financial results and highlighted collaborations that support its platform expansion. Upcoming presentations at major conferences will further discuss the therapy's potential in various clinical settings.
Read more →INKTMiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
MiNK Therapeutics has announced the initiation of a randomized Phase 2 trial for its agenT-797 therapeutic, targeting acute lung injury in partnership with the First Lviv Territorial Medical Union in Ukraine. This trial is designed to evaluate the efficacy of donor-derived iNKT cells added to standard care versus placebo in critically ill patients. The collaboration aims to generate clinically meaningful data that could support future treatments for patients suffering from severe immune dysfunction. Preliminary results are anticipated in the second half of 2026, aiming to improve outcomes in high-acuity critical care settings.
Read more →INKTMiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
MiNK Therapeutics presented data at ASGCT 2026 showing that their iNKT cell therapy, agenT-797, induces context-dependent immune responses in cancer and ARDS patients. The therapy demonstrated significant clinical activity, including complete remission in solid tumors and improved survival in ARDS. The findings support a randomized Phase 2 trial for acute lung injury, with preliminary data expected in 2026.
Read more →INKTMiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
MiNK Therapeutics plans to report its first quarter 2026 financial results on May 15, 2026. The company will also provide updates on its iNKT cell therapy programs, including the lead candidate agenT-797. Recent advancements and collaborations, particularly in pediatric cancer therapies, will be discussed during the conference call.
Read more →INKTMiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
MiNK Therapeutics announced promising Phase II data for agenT-797 in combination with botensilimab and balstilimab, showing a 77% disease control rate in patients with PD-1 refractory gastroesophageal cancer. The study highlighted long-term survival beyond 20 months for some patients and significant improvements in progression-free survival associated with the use of an induction therapy strategy. Although the trial did not meet its primary endpoint regarding overall response rate, the findings provide valuable insights into the treatment's potential. Safety profiles were consistent with existing therapies, and further analysis is ongoing to optimize treatment sequencing and identify suitable biomarkers.
Read more →INKT▲ +7%on this news
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
MiNK Therapeutics announced that data from a Phase II trial of agenT-797, in combination with botensilimab and balstilimab, will be presented at the AACR Annual Meeting 2026. This study focuses on patients with PD-1 refractory gastroesophageal cancer, aiming to explore immune modulation and treatment sequencing. The findings could inform future strategies for managing this challenging cancer type.
Read more →INKTMiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
MiNK Therapeutics announced that their investigational iNKT cell therapy, agenT-797, will be presented at the ASGCT Annual Meeting in May 2026. The abstract highlights the therapy's adaptive immune modulation capabilities in cancer and acute respiratory distress syndrome (ARDS). The presentation will be led by Dr. Terese C. Hammond, showcasing the potential of agenT-797 in clinical applications.
Read more →INKTMiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
MiNK Therapeutics has announced that its abstract on the investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the ATS International Conference 2026. The abstract discusses a novel combination immunotherapy approach for treating unresolving Coccidioides immitis infections. The presentation will take place on May 20, 2026, in Orlando, Florida.
Read more →INKTMiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
MiNK Therapeutics reported its Q4 and full-year 2025 results, highlighting advancements in its Phase 2 programs, including a trial for ARDS set to begin in 1H 2026. The company secured significant non-dilutive funding and is preparing for multiple clinical catalysts in 2026. Despite a net loss increase, the company is optimistic about its future prospects.
Read more →INKTMiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
MiNK Therapeutics, Inc. will report its fourth quarter and full year 2025 financial results on March 31, 2026. The company will also host a conference call to discuss its clinical progress and platform expansion in iNKT cell therapies. A recent collaboration with C-Further and the University of Southampton aims to advance a targeted therapy for pediatric cancers, enhancing MiNK's portfolio and strategic partnerships.
Read more →INKT▲ +29.3%on this news
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
MiNK Therapeutics has partnered with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy aimed at pediatric cancers. The collaboration will receive approximately $1.1 million in non-dilutive funding to support development through key translational milestones. This initiative represents a significant advancement in addressing treatment gaps in childhood cancers with limited options. The partnership will utilize MiNK's iNKT platform, which is designed for broader accessibility and faster delivery of treatments for young patients.
Read more →INKTMiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
MiNK Therapeutics presented new data at the Keystone Symposia highlighting the depletion of invariant natural killer T (iNKT) cells in patients with advanced idiopathic pulmonary fibrosis (IPF). This depletion suggests a mechanistic role in the disease and supports the potential of iNKT cell therapy for restoring immune balance and aiding tissue repair. The findings indicate broader applications for MiNK's iNKT platform in chronic immune-mediated lung diseases.
Read more →INKTMiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
MiNK Therapeutics announced the initiation of a Phase 1 clinical trial for agenT-797, aimed at preventing graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation. The trial, led by the University of Wisconsin–Madison, will assess the therapy's safety and efficacy. Funding from NIH and philanthropic sources supports this innovative approach to improve patient outcomes.
Read more →INKTMiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance
MiNK Therapeutics reported promising Q3 2025 results, showcasing durable remissions and survival in patients with refractory cancers through its lead therapy, agenT-797. The company is advancing its allogeneic invariant natural killer T (iNKT) cell therapies with significant progress in clinical trials, including a newly launched GvHD study funded by NIH grants. The addition of prominent leaders in pulmonary and trauma medicine to the management team further strengthens the company's capabilities as it prepares for pivotal developments across various diseases. A cash position extending through 2026 supports ongoing programs, despite an increase in reported net losses.
Read more →INKTMiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
MiNK Therapeutics has published new preclinical data demonstrating that MiNK-215, an allogeneic iNKT cell therapy, effectively targets FAP-positive cancer-associated fibroblasts in solid tumors. This innovative therapy aims to overcome barriers to immune infiltration and improve treatment outcomes for patients resistant to traditional immunotherapies. The findings highlight MiNK-215's potential as a scalable, off-the-shelf solution for challenging cancer cases.
Read more →INKTMiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
MiNK Therapeutics (NASDAQ: INKT) has reported promising Q3 2025 financial results, highlighting durable clinical responses for its lead asset, agenT-797, which demonstrated significant remissions in refractory cancers. The company is launching a federally funded trial for preventing GvHD in transplant patients and expanding its iNKT platform into inflammatory diseases. With new leadership and continued funding, MiNK aims to advance its pivotal development across multiple high-need areas, including oncology and pulmonary disease. The financial outlook remains optimistic, with a cash runway extended through 2026.
Read more →INKTMiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
MiNK Therapeutics reported promising results for agenT-797, an allogeneic iNKT cell therapy, at the SITC Annual Meeting 2025. The therapy demonstrated durable responses and immune reactivation in patients with advanced solid tumors resistant to other treatments. Notably, some patients experienced remissions lasting over two years. The findings suggest that agenT-797 may redefine the treatment landscape for immune-resistant cancers.
Read more →INKTMiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
MiNK Therapeutics will report its third quarter 2025 financial results on November 14th, following a presentation at the SITC Annual Meeting. The presentation highlighted promising clinical data for the agenT-797 iNKT cell therapy, showing durable immune reconstitution in patients with advanced solid tumors. A conference call will be held to discuss these results and upcoming milestones.
Read more →INKTMiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
MiNK Therapeutics will present late-breaking data on AgenT-797 at the SITC Meeting, showcasing its durable clinical activity in advanced solid tumors. The presentation will provide updated safety and efficacy results from the ongoing Phase 1 study. AgenT-797 is designed to enhance immune response against cancer and is part of MiNK's innovative iNKT cell therapy platform.
Read more →INKTMiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
MiNK Therapeutics has appointed Colonel (Ret.) John B. Holcomb, MD, to its Board of Directors. Dr. Holcomb, an expert in trauma and critical care, will contribute to MiNK's efforts in developing iNKT cell therapies. His experience is expected to enhance the company's clinical rigor and operational excellence as it addresses pressing health issues.
Read more →INKT▼ -5.1%on this newsshared move
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
MiNK Therapeutics announced that CEO Dr. Jennifer Buell will deliver a plenary address at the 10th Annual CAR-TCR Summit in Boston. Her presentation will cover first-in-human data on iNKT cell therapies, showcasing their potential in treating severe immune collapse. The summit gathers leaders in cell therapy to discuss advancements across various diseases.
Read more →INKT▲ +7.8%on this news
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
MiNK Therapeutics has appointed Dr. Terese C. Hammond as Head of Inflammatory and Pulmonary Diseases. Dr. Hammond, a recognized leader in pulmonary medicine, will lead pivotal trials for iNKT therapies, which have shown significant potential in treating severe pulmonary conditions. Her expertise is expected to enhance the company's clinical programs and accelerate development.
Read more →INKT▼ -12.5%on this news
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
MiNK Therapeutics reported strong financial results for Q2 2025, highlighting significant clinical achievements and a robust balance sheet. The company secured non-dilutive funding to advance its allogeneic iNKT cell therapies targeting GvHD. CEO Jennifer Buell emphasized the positive impact of these developments on their oncology and immunology programs.
Read more →INKT▼ -8.3%on this news
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will release its second quarter 2025 financial results on August 14, 2025. The company will host a conference call at 8:30 a.m. ET to discuss these results and provide a corporate update. MiNK specializes in iNKT cell therapies for cancer and immune-mediated diseases.
Read more →INKT▼ -31%on this news· ran to -50% by day 3
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
MiNK Therapeutics announced a publication in Frontiers in Immunology highlighting the potential of iNKT cells as a groundbreaking therapy for solid tumors. The article emphasizes the unique capabilities of iNKT cells, particularly their dual targeting ability and effectiveness in overcoming barriers in tumor treatment. MiNK's lead therapy, agenT-797, has shown promising results in clinical trials, including durable responses in patients with previously untreatable cancers.
Read more →INKT▲ +730.1%on this newsshared move
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
MiNK Therapeutics announced a landmark case of complete remission in a patient with metastatic testicular cancer following treatment with agenT-797, an allogeneic iNKT cell therapy. The patient had previously failed multiple treatments but achieved significant clinical and biochemical remission. This case supports the potential of iNKT therapies in challenging cancers and highlights ongoing clinical trials for further evaluation.
Read more →INKT▲ +5.8%on this news
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
MiNK Therapeutics, a clinical-stage biopharmaceutical company, has scheduled its Annual Shareholders Meeting for June 18, 2025, to be held in a virtual format starting at 9:30 a.m. ET. Registration will begin at 9:15 a.m. ET, and shareholders can access the meeting through a specific link using a control number found in proxy materials. The company continues to develop innovative iNKT cell therapies aimed at various diseases, showcasing its commitment to advancing immune-mediated therapies.
Read more →INKTMiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
MiNK Therapeutics has received a grant from the NIAID to advance its allo-iNKT cell therapy aimed at preventing graft-versus-host disease (GvHD) in patients undergoing stem cell transplants. This grant acknowledges the therapeutic potential of iNKT cells and supports MiNK's collaboration with the University of Wisconsin in improving treatment outcomes. GvHD remains a significant complication with high mortality rates, and the researchers believe that the iNKT cell therapy could effectively manage immune responses while maintaining patients' ability to fight infections. This grant is expected to accelerate MiNK's development efforts in addressing this critical health issue.
Read more →INKTMiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
MiNK Therapeutics, Inc. reported its financial results for Q1 2025, highlighting significant clinical and strategic advancements in its iNKT cell therapy platform. New data shows encouraging results in treating PD-1–resistant gastroesophageal cancers, with a Phase 2 trial currently enrolling. The company is also pursuing potential funding to support its GvHD program, which underscores its commitment to expanding treatment accessibility. Additionally, MiNK has successfully reduced its operational cash burn compared to the previous year, positioning itself for future growth and exploration of novel partnerships.
Read more →INKTMiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
MiNK Therapeutics has announced its financial results for Q4 and the full year 2024, showing significant progress in its clinical and operational activities. The company is advancing its allogeneic iNKT cell therapies, evidenced by encouraging clinical data and active enrollment in trials. Notably, collaborations and an innovative AI-driven drug discovery platform are expected to bolster future growth. Financially, MiNK reported a decrease in net losses compared to the previous year and ended with a stable cash balance.
Read more →INKT▼ -7.9%on this news
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
MiNK Therapeutics, a clinical-stage biopharmaceutical firm, will release its financial results for Q4 and the full year 2024 on March 18, 2025. The company is focused on developing innovative iNKT cell therapies for cancer and immune diseases. A conference call led by MiNK executives will follow the earnings release, providing insights into the company's performance and future strategy. Investors are cautioned about the uncertainties and risks associated with forward-looking statements as outlined in their filings.
Read more →INKT▲ +5.4%on this news
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
MiNK Therapeutics has presented new translational data from its Phase 2 study of allo-iNKT cells, agenT-797, combined with checkpoint inhibitors in patients with refractory gastroesophageal cancer. The findings showcased significant immune reactivation and strong clinical activity, emphasizing the importance of treatment sequencing for optimal outcomes. With this innovative therapy, MiNK aims to enhance the efficacy and accessibility of cancer treatments, heralding a potential breakthrough in the field of immuno-oncology.
Read more →INKTMiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that it has regained compliance with Nasdaq listing requirements. This achievement confirms that MiNK meets the minimum bid price and market value of listed securities necessary for continued listing on The Nasdaq Capital Market. With this compliance, the company can continue its efforts in developing its allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
Read more →INKT▼ -7.9%on this news
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
MiNK Therapeutics announced an upcoming oral presentation at the AACR IO Annual Meeting, scheduled for February 23-26, 2025, in Los Angeles. The presentation will showcase interim data from a Phase 2 study of AgenT-797, an iNKT cell therapy, when combined with Agenus' BOT/BAL combination in patients with refractory gastric cancer. The presentation signifies the company’s commitment to advancing innovative cancer treatments as it explores the potential of its iNKT cell therapy platform.
Read more →INKTMiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
MiNK Therapeutics, a clinical-stage biopharmaceutical company, presented promising data on their innovative iNKT cell therapies at the ASCO GI Symposium. The focus is on the combination of agenT-797 with botensilimab and balstilimab aimed at treating advanced gastroesophageal cancers in previously treated patients. Preliminary results suggest durable responses and tolerability, particularly in patients with gastric cancer. Further updates from the ongoing Phase II study are expected in late 2025.
Read more →INKT▼ -14%on this news
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
MiNK Therapeutics, a clinical-stage biopharmaceutical firm, will present a Phase 2 study of its agenT-797 therapy for refractory gastric cancer at the ASCO GI Annual Meeting in January 2025. The study investigates the efficacy of combining agenT-797 with Agenus's botensilimab and balstilimab. Abstracts will be published on January 21, 2025, and can be accessed via MiNK's website post-conference. This presentation highlights promising developments in the company's iNKT cell therapy pipeline.
Read more →INKT▼ -5.6%on this news
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
MiNK Therapeutics, a clinical-stage biopharmaceutical company, reported its third-quarter results for 2024, highlighting continued progress in its iNKT cell therapy platform aimed at treating cancer and immune-mediated diseases. The company announced a new board appointment and a research collaboration with Autonomous Therapeutics to develop therapies targeting metastatic tumors. Although MiNK reported a financial loss, it noted a reduction in cash used for operations compared to the previous year. The company's ongoing clinical programs and upcoming data presentations are anticipated to bolster its efforts in the oncology sector.
Read more →INKTMiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will release its third quarter 2024 financial results on November 14, 2024. The company is known for pioneering allogeneic iNKT cell therapies aimed at treating cancer and immune-mediated diseases. Executives will discuss the financial outcomes and provide a corporate update during a scheduled conference call. Forward-looking statements regarding the potential of iNKT cells come with several risks that could affect expected outcomes.
Read more →INKTMiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
MiNK Therapeutics presented promising data from its iNKT cell therapy programs at SITC 2024, emphasizing the combination potential of agenT-797 with existing immunotherapies. The therapies target PRAME-positive solid tumors and are aimed at improving outcomes for patients with limited treatment options. AgenT-797 demonstrated durable disease control in heavily pretreated patients. The company aims for scalable and accessible solutions for refractory solid tumors through these innovative approaches.
Read more →INKTMiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
MiNK Therapeutics has appointed Dr. Robert Kadlec to its Board of Directors, enhancing its leadership in biodefense and public health strategy. Dr. Kadlec's extensive background includes significant roles during the COVID-19 pandemic and expertise in addressing public health emergencies. His involvement is anticipated to advance MiNK's innovative iNKT cell therapies, which target critical conditions like ARDS and other immune-related diseases. This strategic appointment is seen as a crucial move for the company's growth and its mission to tackle urgent global health challenges.
Read more →INKTMiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
MiNK Therapeutics has entered into a collaboration with Autonomous Therapeutics to develop new therapies aimed at effectively treating metastatic tumors. The partnership will utilize Autonomous' encrypted RNA technology alongside MiNK's iNKT cell therapies, specifically targeting challenging solid tumors. They plan to initiate a Phase 1 clinical trial for patients with treatment-resistant metastatic solid tumors, building on promising preclinical results. This collaboration highlights the potential advancements in cancer treatment through innovative therapeutic approaches.
Read more →INKTMiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that it will present new preclinical data from its iNKT cell programs at the upcoming SITC 2024 Annual Meeting in Houston, Texas. The presentations will focus on two key therapies, agenT-797 and PRAME-TCR, which are aimed at enhancing cancer treatment modalities. The data highlights the potential for combining agenT-797 with next-generation immune checkpoint inhibitors to improve anticancer responses. The meeting will take place from November 6-10, 2024, with the specific presentations scheduled for November 8th and 9th.
Read more →INKTMiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
MiNK Therapeutics (NASDAQ: INKT) will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11th, where CEO Dr. Jennifer Buell is scheduled to conduct a fireside chat. The event provides an opportunity for investor engagement and showcases the company's commitment to transparency. A replay of the chat will be available on their website after the event. MiNK is focused on advancing its pipeline of invariant natural killer T cell therapies aimed at treating cancer and immune-mediated diseases.
Read more →INKTMiNK Reports Second Quarter 2024 Results and Business Update
MiNK Therapeutics, Inc. has reported its second quarter 2024 results, highlighting key advancements in its iNKT cell therapy programs. The company is progressing its lead program, agenT-797, through a Phase 2 study for second-line gastric cancer and has expanded access in treating ARDS, demonstrating promising clinical outcomes. Additionally, MiNK is expecting to activate a Phase 1 study in GvHD in the second quarter of 2024. Financially, the company has improved its cash position following a recent funding round, enhancing its operational runway into 2025.
Read more →INKTMiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
MiNK Therapeutics, Inc. will release its financial results for the second quarter of 2024 on August 13, 2024, before market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. The company, which specializes in allogeneic iNKT cell therapies for cancer and immune-mediated diseases, emphasizes its commitment to innovation in biopharmaceutical development.
Read more →INKTMiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
MiNK Therapeutics, Inc. has announced that it has regained compliance with the Nasdaq Capital Market's market value of listed securities requirement. The confirmation from NASDAQ was received on July 23, 2024, indicating that the company now meets the necessary criteria for continued listing. This news reflects positively on MiNK's operational status and market standing.
Read more →INKTMiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
MiNK Therapeutics presented data on agenT-797 at the ATS Annual Meeting, highlighting its potential in treating severe ARDS in an immune-compromised patient. The case involved a 26-year-old post-renal transplant patient who developed severe hypoxemic respiratory failure due to COVID-19. Following a single dose of agenT-797, notable clinical improvements were observed, including reduced inflammatory markers and eventual recovery. This presentation underscores the need for innovative therapies in acute critical illness.
Read more →INKT▲ +14.3%on this news
MiNK Reports First Quarter 2024 Results
MiNK Therapeutics, Inc. reported its first quarter 2024 results, highlighting significant advancements in its iNKT cell therapy programs. The company successfully raised $5.8 million through a private placement, aimed at accelerating its investigational MiNK-215 therapy into clinics. Key presentations are scheduled for the ATS meeting regarding agenT-797's efficacy in severe respiratory distress. Financially, the company noted a decrease in operational losses compared to the previous year, although it still recorded a net loss of $3.8 million for the quarter.
Read more →INKT▲ +8.9%on this news· ran to +24% by day 1shared move
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
MiNK Therapeutics has announced a $5.8 million private placement to fund the clinical development of its CAR-iNKT therapy, MiNK-215, targeting solid tumors. The funding comes at a 25% premium, with the transaction expected to close on May 14, 2024. Additionally, Yekaterina Chudnovsky has been appointed as a Board Observer, bringing significant experience in medical research advocacy. MiNK-215 aims to address limitations of traditional immune checkpoint inhibitors, especially in treating MSS colorectal cancer with metastatic liver disease.
Read more →INKTMiNK to Provide Corporate Update and First Quarter 2024 Financial Report
MiNK Therapeutics, Inc. is set to release its Q1 2024 financial results on May 14, 2024, prior to market opening. The company will hold a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a corporate update. MiNK specializes in allogeneic iNKT cell therapies for treating cancer and immune-mediated diseases, showcasing its commitment to innovation in biopharmaceuticals.
Read more →INKT▼ -15.4%on this news· ran to -35% by day 1
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
MiNK Therapeutics has revealed encouraging preclinical results for MiNK-215, an investigational CAR-iNKT cell therapy, during the AACR meeting. The therapy demonstrated significant anti-tumor activity in human organoid models, particularly against colorectal cancer liver metastases. MiNK-215 aims to overcome limitations of traditional immunotherapy and could enhance treatment when combined with other therapies. The announcement offers hope for patients with few remaining treatment options.
Read more →INKTMiNK Reports Fourth Quarter and Year-End 2023 Results
MiNK Therapeutics announced its fourth quarter and full-year 2023 results, highlighting advancements in allogeneic iNKT cell therapies, particularly in gastroesophageal cancers and acute respiratory distress syndrome (ARDS). The company has launched a Phase 2 trial for their lead program, agenT-797, showcasing promising survival rates in ARDS patients. Additionally, MiNK established a collaboration with Immunoscape for TCR-based therapies and experienced a significant financial loss, prompting concerns about cash reserves for future operations. The firm continues to focus on addressing unmet needs in cancer treatment and respiratory care.
Read more →INKTMiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
MiNK Therapeutics, Inc. will release its fourth quarter and full year 2023 financial results on March 21, 2024, before market opening. The company will also host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. MiNK Therapeutics specializes in developing allogeneic iNKT cell therapies aimed at treating cancer and immune-mediated diseases.
Read more →INKTMiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
MiNK Therapeutics announced the presentation of promising preclinical data for MiNK-215 at the AACR 2024 meeting. This IL-15 armored FAP-targeting CAR-iNKT cell therapy demonstrated its effectiveness in enhancing T cell-mediated tumor killing in colorectal cancer liver metastases using human organoid models. The findings suggest MiNK-215's potential to address significant challenges posed by liver metastases and improve therapeutic outcomes when combined with immune checkpoint inhibitors. MiNK highlights the unique capabilities of iNKT cells in overcoming immune suppression in the liver environment.
Read more →INKT▲ +10.3%on this news
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
MiNK Therapeutics announced the publication of a phase 1/2 study in Nature Communications, highlighting promising results of their product, agenT-797, for treating patients with severe acute respiratory distress syndrome (ARDS) due to SARS-CoV-2. The study involved a cohort of 21 patients, showing more than 70% survival rates, with even higher rates among those on mechanical ventilation. The findings indicate that agenT-797 can not only improve survival but also reduce secondary infections, presenting a favorable safety profile. Future clinical trials for agenT-797 in viral ARDS are planned.
Read more →INKTMiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
MiNK Therapeutics recently announced promising results from a phase 1/2 study of their iNKT cell therapy, agenT-797, published in Oncogene. The case report details a durable partial response in a gastric cancer patient who had previously shown resistance to anti-PD-1 treatments. The study underscores the unique abilities of iNKT cells to overcome immune checkpoint inhibitor resistance in solid tumors. MiNK is advancing its research in this field with further updates expected in the near future.
Read more →INKT▼ -6.7%on this news· ran to -20% by day 3
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK Therapeutics, Inc. announced its third-quarter 2023 financial results, highlighting promising data for its iNKT cell therapy, agenT-797. The therapy has shown durable clinical benefits in solid tumors and potential application in other diseases like severe respiratory distress. Despite reporting a decline in cash reserves and a net loss of $17 million, the company plans to advance its clinical trials and expand its product offerings. A conference call is scheduled for November 9, 2023, to discuss these results and future directions.
Read more →INKT▲ +13.6%on this news
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
MiNK Therapeutics, Inc. presented promising clinical data on its allogeneic iNKT cell therapy, agenT-797, at the SITC 2023 conference. The therapy demonstrated durable clinical responses and long-term persistence in patients with solid tumors, including gastric cancer. Additionally, there were no dose-limiting toxicities reported, signaling a tolerable safety profile. MiNK is advancing further clinical studies, including a randomized phase 2 trial by year-end 2023 to evaluate agenT-797 in combination with standard chemotherapy.
Read more →INKT▲ +7.6%on this news
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
MiNK Therapeutics, Inc. (NASDAQ: INKT) has announced the upcoming release of its third quarter 2023 financial results, scheduled for November 9, 2023. As a clinical-stage biopharmaceutical company, MiNK is focused on developing allogeneic iNKT cell therapies for cancer and other immune-mediated diseases. The company's work emphasizes scalable and reproducible manufacturing, positioning it as a key player in therapeutic innovation within its sector.
Read more →INKTMiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced it will present updated clinical data on its allogeneic iNKT cell therapy, agenT-797, during the Society for Immunotherapy of Cancer's 38th Annual Meeting from November 1-5, 2023. The presentation will include insights on agenT-797’s mechanism of action in treating solid tumors, showing the company's commitment to innovate in cancer treatment. Dr. Marco Purbhoo, Head of Translational Research, will present the findings.
Read more →INKT▼ -8.2%on this news
MiNK Therapeutics to Participate in September Investor Conferences
MiNK Therapeutics, a clinical-stage biopharma company focused on iNKT cell therapies, announced its participation in two upcoming investor conferences in September 2023. CEO Dr. Jennifer Buell will be presenting at the Baird 2023 Global Healthcare Conference on September 12 and at the HC Wainwright 25th Annual Global Investment Conference on September 13. The events will provide opportunities for the company to showcase its innovative approach to cancer and immune-mediated disease treatments.
Read more →INKT▲ +6.7%on this news
MiNK Therapeutics Reports Second Quarter 2023 Results
MiNK Therapeutics provided an update on their clinical progress and financial results for Q2 2023. The company is set to launch a Phase 2 trial for its lead compound, agenT-797, in metastatic gastric cancer at Memorial Sloan Kettering Cancer Center. Promising data was reported for agenT-797 and their novel therapy MiNK-215, with both showing significant clinical benefits in various cancer types, including improved survival in patients suffering from respiratory distress due to COVID-19. However, the company also reported a decline in cash reserves and a moderate net loss over the previous year.
Read more →INKTMiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced their plans to release the second quarter 2023 financial results on August 10, 2023. CEO Jennifer Buell will also participate in the BTIG Virtual Biotechnology Conference on August 8, providing updates on the company's portfolio. This participation signals the company's efforts to maintain investor relations and boost visibility in the market.
Read more →INKT▲ +16.9%on this news
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
MiNK Therapeutics presented promising clinical data on its allogeneic iNKT cell therapy, agenT-797, for patients with COVID-19 associated Acute Respiratory Distress Syndrome (CARDS) at the ATS International Conference. The study demonstrated a 75% survival rate in patients on extracorporeal membrane oxygenation after receiving the treatment, compared to just 30% for controls. Additionally, agenT-797 led to significant improvements in lung function and a reduction in secondary infections, highlighting its potential as an effective therapy in acute respiratory conditions. The company plans to advance this treatment through externally financed programs.
Read more →INKTMiNK's Novel FAP-CAR-iNKT Presented at ASGCT
MiNK Therapeutics recently presented promising preclinical data on its iNKT cell therapy candidate, MiNK-215, at the ASGCT annual meeting. This innovative therapy targets fibroblast activation proteins in cancer cells and has shown significant anti-tumor activity in non-small cell lung cancer models. The company is advancing towards an IND filing, expected in 2024, to further evaluate MiNK-215's therapeutic potential. The findings underscore the candidate's ability to disrupt the tumor microenvironment and enhance the anti-tumor immune response.
Read more →INKT▲ +7.3%on this news
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
MiNK Therapeutics reported significant advancements in its clinical programs and financial results for Q1 2023. The company's lead product, agenT-797, demonstrated clinical efficacy in heavily pre-treated solid tumor cancers, particularly in patients with metastatic gastric cancer. MiNK is commencing phase 1/2 expansion studies in NSCLC and gastric cancer, supported largely by non-dilutive grant funding. However, the company's cash reserves declined from the previous quarter, and they posted a net loss of $5.7 million.
Read more →INKT▼ -8.3%on this news· ran to -57% by day 3
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
MiNK Therapeutics, a clinical-stage biopharmaceutical company, will report its first quarter 2023 financial results on May 11, 2023, before market opening. The leadership team will host a conference call at 8:30 a.m. ET to discuss these results and provide an update on corporate matters. Investors can access the call via dial-in numbers and also through a live webcast on the company's website.
Read more →INKTMiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
MiNK Therapeutics presented promising clinical data on their allogeneic iNKT cell therapy, agenT-797, at the AACR Annual Meeting. The therapy showed activity in patients with refractory solid tumors, achieving a notable 42% tumor shrinkage in a gastric cancer patient who previously did not respond to other treatments. AgenT-797's unique capabilities include generating immune responses without requiring lymphodepletion, and it has a favorable safety profile. The company plans to advance agenT-797 into further clinical trials to evaluate its effectiveness in combination with standard treatments.
Read more →INKTMiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
MiNK Therapeutics reported its financial results for the fourth quarter and full year 2022, highlighting significant advancements in its iNKT cell therapy pipeline. The company has experienced clinical progress, especially with AgenT-797, which is showing promising results in solid tumors. Despite these advancements, MiNK reported a decline in cash reserves and a net loss for the year, raising concerns about its financial future. The company plans to expand its clinical studies and manufacturing capabilities going forward, with data presentations scheduled for 2023.
Read more →INKT▼ -5.6%on this news
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
MiNK Therapeutics, Inc. has announced that it will present updated clinical data on its allo-iNKT cell therapy, agenT-797, during the AACR Annual Meeting scheduled for April 14-19, 2023. The presentation will include insights into the therapy's application in treating advanced solid tumors, both alone and in combination with approved anti-PD-1 treatments. The update signifies the company's ongoing efforts in pioneering iNKT cell therapies for cancer treatment.
Read more →INKT▲ +7.3%on this news
MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that it will release its financial results for Q4 and the full year of 2022 on March 21, 2023. The company specializes in developing iNKT cell therapies aimed at treating cancer and immune-mediated diseases. During the announcement, MiNK's leadership will host a conference call at 8:30 a.m. ET to discuss these results and provide a corporate update. This indicates proactive investor communication and commitment to transparency.
Read more →INKTMiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference
MiNK Therapeutics, a clinical-stage biopharmaceutical company, announced that its President and CEO, Dr. Jennifer Buell, will participate in a fireside chat at the HC Wainwright Cell Therapy Virtual Conference scheduled for February 28th. This event underscores MiNK's focus on allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Access to the live chat will be available online, with a replay accessible on the company's website afterward.
Read more →INKTMiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
MiNK Therapeutics, a clinical-stage biopharmaceutical firm, announced that Dr. Jennifer Buell, its President and CEO, will engage in a fireside chat during the B. Riley Securities Oncology Conference on January 18th. This participation showcases the company's innovative work in developing iNKT cell therapies for cancer treatment. The event will also include discussions with other industry leaders, highlighting advancements in oncology therapies. The conference itself aims to explore new treatment modalities and improve the standard of care for cancer patients.
Read more →INKT▼ -5.9%on this news· ran to -21% by day 3
MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other im
Read more →INKT▼ -12.8%on this news
MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilization First immune ce
Read more →INKT▲ +5.6%on this news· ran to +18% by day 3
MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results
- Five presentations on clinical data and novel pipeline candidates at the Society of Cancer Immunotherapy (SITC) Meeting - R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via webcast NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clini
Read more →INKTMiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other im
Read more →INKT▲ +6.8%on this news
MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Clinical data on AgenT-797, allogeneic (allo) iNKTs, +/- anti-PD-1 in advanced solid tumors Clinical data of AgenT-797 in viral ARDS and refractory multiple myeloma New therapeutic candidates: 1) MiNK-215, an allo-FAP-CAR-iNKT; 2) MiNK-413, allo-armored-BCMA-CAR-iNKT NEW YORK,
Read more →INKT▲ +6.8%on this news
MiNK Therapeutics to Host R&D Event November 10, 2022
Experts in disease pathways discuss clinical data of allo-iNKTs R&D strategy driving pipeline momentum, productivity, and innovation Internal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 doses R&D event: November 10th from 4:00-6:00 pm E
Read more →INKT▲ +14.3%on this news
MiNK Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other im
Read more →INKTMiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results
Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023 Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022 Under the leadership team of Dr. Joy Zhou, completed internal cGMP production of AgenT-797 with expansion capacit
Read more →INKTMiNK Therapeutics to Participate at BTIG Biotechnology Conference
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other im
Read more →INKT▲ +6.1%on this news
MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update
NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other im
Read more →INKT▼ -13.6%on this news· ran to -27% by day 1
MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022 GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr BCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022 Ended First Quarter with $34.7M in cash with a project
Read more →INKT▲ +15.2%on this news
MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other i
Read more →INKTMiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
AgenT-797 (Allo-iNKTs) +/- anti-PD-1 clinical trial underway in solid tumor cancers Benefit in severe COVID-19 ARDS shows 75% survival rate in patients treated with Allo-iNKTs AgenT-797 treatment with no lymphodepletion shows no cytokine release syndrome or neurotoxicity 2021
Read more →INKTMiNK Therapeutics to Report Fourth Quarter & Full Year 2021 Financial Results and Business Update
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other i
Read more →INKTMiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers
Clinical data show AgenT-797 can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity Clinical trials underway in solid tumor cancers, multiple myeloma, and viral ARDS NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Mi
Read more →INKT▲ +7.7%on this news
MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference
NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m
Read more →INKT▲ +5%on this news
MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m
Read more →INKTMiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797
No evidence of neurotoxicity or cytokine release syndrome Early signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma iNKTs demonstrated potent tumor killing in solid tumor models NEW YORK, Nov. 12, 2021 (GLOBE
Read more →INKTMiNK Therapeutics Presents New Preclinical and Clinical Data on iNKT Cell Therapy Programs at SITC 2021
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m
Read more →INKTMiNK Therapeutics Announces Closing of Initial Public Offering
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m
Read more →INKTMiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and oth
Read more →INKTMiNK Therapeutics to Present Three Abstracts on Novel Allogeneic iNKT Programs at SITC
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-m
Read more →INKTMiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common sto
Read more →Competitive Position
How INKT ranks across every disease it competes inCompetitive Position is a premium feature
See how INKT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial